Immutep Ltd has released a press release.
Appendix 4E & 2024 Full Year Statutory Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- TACTI-003 data selected for oral presentation at ESMO 2024
- First Participant Dosed in Phase I Study of IMP761
- Successful Meeting with FDA on Phase III Design in NSCLC
- Regulatory Clearance received for Phase 1 trial of IMP761
- Webcast to discuss data presented at ESMO Plenary Session
Later from Immutep
- S&P DJI Announces September 2024 Quarterly Rebalance
- New Positive Efficacy Data for Efti in Head and Neck Cancer
- Immutep receives A$3.6 million French R&D Tax Incentive
- Enrolment for Ph II AIPAC-003 Breast Cancer Trial Completed
- Positive Data from Phase II Trial in Soft Tissue Sarcoma
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep